Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-390-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A combined repeated dose/reproduction screening toxicity study with Tallow tripropylenetetraamine is available, leading to a LOAEL of 30 mg/kgbw/day based on foamy macrophage infiltration in the ileum and jejunum and foamy macrophage foci found in the mesenteric lymph nodes observed at this dose level. Cross-reading to a 90 day oral study (OECD 408, GLP) on Tallow dipropylenetriamine results to a NOAEL of 2.5 mg/kg bw/day, based on foamy macrophage infiltration in the ileum and jejunum.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 22NOV2012 - 10APR2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study performed according to OECD guideline and GLP principles.
- Justification for type of information:
- (See also Category polyamines in support of Tetraamine T - 20120420.pdf attached to Ch.13)
Longer chain polyamines, i. e. increasing number of DP-groups (1,3-diamine propane), result to lower toxicity. As a consequence, results from a triamine can be considered as a worst case approach for a tetramine with same alkyl chain. - Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.26 (Sub-Chronic Oral Toxicity Test: Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3100 (90-Day Oral Toxicity in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Chemical Substances Control Law 1973, Notification of Mar. 31 2012 by MHLW (0331 No.7), METI (No. 5) and MOE (No. 110331009)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:WI(Han)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: approximately 6 weeks
- Weight at study initiation: 140 - 164g (males) and 96 - 135g (females)
- Housing: group housing of 5 animals per sex in Macrolon cages, individual housing in a Hi-temp polycarbonate cage during locomotor activity monitoring
- Diet: pelleted rodent diet, ad libitum (except during motor activity measurements and overnight before sacrifice)
- Water: tap water, ad libitum (except during motor activity measurements and overnight before sacrifice)
- Acclimation period: >5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-24
- Humidity (%): 40-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 22NOV2012 To: 10APR2013 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Justification for use and choice of vehicle:
Based on trial formulations performed at WIL Research Europe and on information provided by the sponsor.
- Concentration in vehicle:
0, 0.5, 2, 8 and 32 mg/ mL
- Amount of vehicle (if gavage):
5mL/kg
From Day 1 to Day 28 formulations (w/w) were prepared daily within 5 hours prior to dosing. From Day 29 onwards, formulations (w/w) were prepared for a maximum of 8 days prior to dosing. For formulations prepared for dosing between Days 1 and 7, the test substance was liquefied prior to weighing by heating in a water bath up to 57.6⁰C for 2 hours and 32 minutes. From Day 8 onwards, the test substance was not heated but scraped out of the container instead. Formulations were homogenized to a visually acceptable level. In order to obtain homogeneity, the formulations were heated in a water bath up to 59.8⁰C for a maximum of approximately 15 minutes. The formulations were allowed to cool down to a temperature of maximally 36.1⁰C prior to dosing. Adjustment was made for density of the test substance and specific gravity of the vehicle. No correction was made for the purity/composition of the test substance. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- In week 1, 26 samples were collected. In week 6, 18 samples were collected. Group 1 was the control group. Group 2, 3, 4 and 5 were dosed at 2.5, 10, 40 and 160 mg/kg bw/day, respectively. The samples of the control group, Group 3 and Group 4 were taken in duplicate from the middle position of the container and immediately stored on dry ice. Samples of treatment groups 2 and 5 were taken in duplicate from the top, middle and bottom position of the container. In addition, stability samples were taken from formulation groups 2 and 5 in week 1, in 4-fold at the middle position of the container. A pair of them were stored for 5 hours at room temperature under normal laboratory light conditions and then placed on dry ice under nitrogen, and the other pair of stability samples were stored for 8 days under nitrogen at room temperature immediately after sampling. In week 13, 16 samples were collected. Group 1 was the control group, Group 2, 3 and 4 were dosed at 2.5, 10 and 40 mg/kg bw/day, respectively. The samples of the control group and Group 3 were taken in duplicate from the middle position of the container and immediately stored on dry ice. Samples of treatment groups 2 and 4 were taken in duplicate from the top, middle and bottom position of the container.
The accuracy of preparation was considered acceptable if the mean measured concentrations were 85-115% of the target concentration. Homogeneity was demonstrated if the coefficient of variation was ≤ 10%. Formulations were considered stable if the relative difference before and after storage was maximally 10%. - Duration of treatment / exposure:
- at least 90 days
- Frequency of treatment:
- once daily, 7 days per week
- Remarks:
- Doses / Concentrations:
0, 2.5, 10, 40 and 160 mg/kg
Basis:
actual ingested - No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Dose levels were based on results of a 14-day dose range finding study. - Positive control:
- None
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least twice daily.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least once daily from start of treatment onwards. Once prior to start of treatment and at weekly intervals, this was also performed outside the home cage in a standard arena.
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly, more often if required by health status.
FOOD CONSUMPTION:
- Weekly
WATER CONSUMPTION:
- Subjective appraisal (no quantitative investigation)
OPHTHALMOSCOPIC EXAMINATION: Yes
- At pretest : All animals (including spare animals)
- At Week 11: All surviving animals dosed at 160 mg/kg bw/day
- At Week 13: All animals dosed with 0or 40 mg/kg bw/day
HAEMATOLOGY: Yes
- Time schedule for collection of blood: after necropsy (or after sacrifice in extremis)
- Anaesthetic used for blood collection: Yes (isofluran)
- Animals fasted: Yes
- How many animals: All
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: after necropsy (or after sacrifice in extremis)
- Animals fasted: Yes
- How many animals: All
URINALYSIS: No data
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: after dosing at no specific time point, but within a similar time period after dosing for the respective animals (all animals dosed with 0 - 40 mg/kg bw/day in Week 12, and all surviving animals at 160 mg/kg bw/day in Week 11
- Battery of functions tested: hearing ability and locomotor activity, pupillary reflex, static righting reflex and grip strength
OTHER:
- All females had a daily vaginal lavage from Day 72 up to and including Day 92 females exposed to 0, 2.5, 10 or 40 mg/kg bw/day (or up to Day 77 for surviving females exposed to 160 mg/kg bw/day) to determine the stage of estrous. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- The following statistical methods were used to analyze the data:
− If the variables could be assumed to follow a normal distribution, the Dunnett-test (many-to-one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
− The Steel-test (many-to-one rank test) was applied if the data could not be assumed to follow a normal distribution.
− The Fisher Exact-test was applied to frequency data.
− The Kruskal-Wallis nonparametric ANOVA test was applied to motor activity data to determine intergroup differences. In case intergroup differences were seen, the Wilcoxon test was applied to compare the treated groups to the control group.
All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance. Group means were calculated for continuous data and medians were calculated for discrete data (scores) in the summary tables. Test statistics were calculated on the basis of exact values for means and pooled variances. Individual values, means and standard deviations may have been rounded off before printing. Therefore, two groups may display the same printed means for a given parameter, yet display different test statistics values. - Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
At 160 mg/kg bw/day, 3/10 males and 5/10 females were killed in extremis between Days 57 and 73 (with one early sacrifice on Day 18). Based on the high mortality rate and signs of deteriorated health condition of animals at 160 mg/kg bw/day, the remaining animals were sacrificed on Day 77. At 40 mg/kg bw.day, 3/10 males were killed in extremis in the last week of treatment (Day 86 or 88). At 10 mg/kg bw/day, 1 male was found dead in Week 12 (Day 84). No mortality occurred at 2.5 mg/kg. At 160 mg/kg bw/day, swelling of the snout, abdomen, forelegs and/or hindlegs was seen in most males and females from Week 9 onwards, and abdominal swelling was also noted for the male rat that died early on in the treatment phase in Week 3. All males and females showed a hunched posture from Week 2 (males) or Week 4 (females) onwards. Further signs at the high dose included breathing difficulties, and at lower incidence, uncoordinated movements, lethargy, piloerection, pallor, chromodacryorrhoea and a lean appearance (primarily in the second week of treatment). At 40 mg/kg bw/day, swelling of the hindlegs and of the area surrounding the testicles was seen at the end of treatment in 4/10 males (three of which were sacrificed) in combination with an abnormal and/or hunched posture, and abnormal gait. One female at 40 mg/kg bw/ daywas noted with swelling of the abdomen on a few days in Week 12 only, and two females displayed a hunched posture from Week 12 onwards. At 10 mg/kg bw/day, one female showed a transient swelling of the hindleg in Week 2 of treatment, and no further changes were seen in this animal. At 2.5 mg/kg bw/day, no clinical signs were noted.
Excessive salivation seen after dosing in a dose-related manner from 10 mg/kg onwards was considered to be a physiological response rather than a sign of systemic toxicity and may be related to irritancy/taste of the test substance. Other clinical signs, including scabs and alopecia, occurred within the range of background findings to be expected for rats of this age and strain which are housed and treated under the conditions in this study. At the incidence observed, these were considered signs of no toxicological significance.
BODY WEIGHT AND WEIGHT GAIN
At 160 mg/kg bw/day, body weights and body weight gain were lower than controls in males from Week 2 onwards, achieving a level of statistical significance on most occasions. Group mean body weight after 11 weeks of treatment was approximately 23% lower than control mean weight. Females showed a normal body weight development. At 40 mg/kg bw/day, a statistically significantly lower body weight (gain) was noted in males from Week 11 onwards. Group mean body weight at the end of treatment was approximately 11% lower than control mean weight. Females showed a normal body weight development. At 2.5 and 10 mg/kg bw/day, body weights were similar to controls throughout treatment. No toxicological relevance was ascribed to the slightly higher body weight or body weight gain on one occasion in females at 40 and 160 mg/kg bw/day, as these variations did not show a relation to the dose and duration of treatment.
FOOD CONSUMPTION
At 160 mg/kg bw/day, a lower food consumption was noted for males throughout treatment, achieving a level of statistical significance on most occasions. When corrected for body weight (relative food consumption), these changes were less apparent and achieved a level of statistical significance on a few occasions only. Relative food intake of females at 160 mg/kg bw/day appeared slightly lower in week 10 and 11 (without statistical significance). At 40 mg/kg bw/day, a statistically significant lower food consumption was noted for males from Week 12 onwards. At 2.5 and 10 mg/kg bw/day, food intake was similar to control levels. No toxicological relevance was ascribed to a slightly higher food consumption of females at 40 mg/kg bw/day in Week 1, as this variation did not show a relation to the dose and duration of treatment.
WATER CONSUMPTION
No unexpected observations noted.
OPHTHALMOSCOPIC EXAMINATION
No toxicologically significant ophthalmology findings were noted. Incidental ophthalmology findings at pretest and/or at end of scheduled treatment consisted of (multi-)focal corneal opacity, focal corneal oedema, pallor of the retina and haemorrhage from the hyaloid vessel. The nature and incidence of these findings was within the range considered to be normal for rats of this age and strain.
HAEMATOLOGY
The following statistically significant changes in haematology parameters distinguished treated animals from control animals:
− Higher total white blood cell counts (WBC) in males and females at 40 and 160 mg/kg bw/day,
− Higher relative neutrophil counts in males at all doses and females at 10, 40 and 160 mg/kg bw/day,
− Lower relative lymphocyte counts in males and females at 10, 40 and 160 mg/kg bw/day,
− Prolonged prothrombin time (PT) in males at 160 mg/kg and females at 40 and 160 mg/kg bw/day,
− Higher platelet counts in males and females at 160 mg/kg bw/day.
Haematological changes in the male at 160 mg/kg bw/ day that was sacrificed in extremis in Week 8 primarily consisted of white blood cell changes similar to those encountered for animals that were sacrificed in Week 11 of the study.
The statistically significant changes in red blood cell parameters at 160 mg/kg bw/day in males and females were primarily due to one male and one female, and means remained (essentially) within the range considered normal for rats of this age and strain. These changes at 160 mg/kg bw/day, as well as changes in red blood cell parameters at lower dose levels were therefore considered not adverse in nature and consisted of:
− Lower red blood cell counts in females at 160 mg/kg bw/day,
− Higher reticulocyte counts in males at 160 mg/kg bw/day (mainly due to one high value for one male and not statistically significant)
− Higher red cell distribution width (RDW) in males at 160 mg/kg (mainly due to one high value for onemale),
− Lower haemoglobin and haematocrit levels in males at 160 mg/kg and in females at 10, 40 and 160 mg/kg bw/day,
− Lower mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH) values in males at 40 and 160 mg/kg bw/day and in females at 40 mg/kg bw/day,
− Lower mean corpuscular haemoglobin concentration (MCHC) in males at 160 mg/kg bw/day and females at 40 and 160 mg/kg bw/day.
The lower relative monocyte, eosinophil and basophil counts in males and/or females at 40 and/or 160 mg/kg bw/day were due to the higher white blood cell counts, as absolute values remained essentially similar to control levels. The shortened activated partial thromboplastin time (APTT) in females at 160 mg/kg bw/day was considered not toxicologically relevant as the mean was only just outside the range considered normal for rats of this age and strain, and since the opposite effect (i.e. a prolonged time) would be expected in case of target organ toxicity.
Any further statistically significant changes in haematological parameters were also considered to be of no toxicological significance as they occurred in the absence of a dose-related trend and/or remained within the range considered normal for rats of this age and strain. These changes consisted of a higher relative monocyte count in females at 10 mg/kg bw/day, higher reticulocyte count in females at 40 mg/kg bw/day, and higher activated partial thromboplastin time in females at 2.5 mg/kg bw/day.
CLINICAL CHEMISTRY
The following (statistically significant) changes in clinical biochemistry parameters distinguished treated animals from control animals:
− Higher alanine aminotransferase activity in males and females at 160 mg/kg bw/day,
− Higher aspartate aminotransferase activity level in females at 160 mg/kg bw/day,
− Higher alkaline phosphatase activity level in females at 160 mg/kg bw/day,
− Lower total protein level in males at 160 mg/kg bw/day (not statistically significant) and females at 40 and 160 mg/kg bw/day,
− Lower albumin level in males and females at 40 and 160 mg/kg bw/day,
− Lower total bilirubin level in males at 40 and 160 mg/kg bw/day and females at 160 mg/kg bw/day,
− Lower urea level in females at 160 mg/kg bw/day,
− Lower creatinine level in males and females at 160 mg/kg bw/day (not statistically significant for females),
− Lower glucose level in males at 160 mg/kg bw/day,
− Lower cholesterol level in males at 40 and 160 mg/kg bw/day,
− Higher potassium level in males and females at 160 mg/kg bw/day,
− Lower chloride level in males and females at 160 mg/kg bw/day,
− Lower calcium level in females at 160 mg/kg bw/day,
− Higher inorganic phosphate level in males at 10, 40 and 160 mg/kg bw/day.
Clinical biochemistry changes in the male at 160 mg/kg that was sacrificed in extremis in Week 8 primarily consisted of higher aspartate and alanine aminotransferase activity, higher potassium and inorganic phosphate level, and lower albumin, total bilirubin and cholesterol level. Any other statistically significant changes in clinical biochemistry parameters were considered to be of no toxicological significance as they occurred in the absence of a dose-related trend-related distribution and remained within the range considered normal for rats of this age and strain. These changes included higher sodium and chloride level in males at 10 mg/kg, higher calcium level in males at 2.5 mg/kg, and lower inorganic phosphate level in females at 2.5 mg/kg.
NEUROBEHAVIOUR
Males and females at 160 mg/kg bw/day showed a reduced motor activity (only statistically significant for males). Motor activity of animals at 40 mg/kg bw/day was similar to controls and showed a similar motor activity habituation profile with high activity in the first interval that decreased over the duration of the test period. No toxicologically significant effects on hearing ability, pupillary reflex, static righting reflex and grip strength were observed among the (surviving) animals at 40 and 160 mg/kg bw/day. A delayed pupillary reflex was noted for one of the eyes of one male at 160 mg/kg bw/day (this animal also showed a delayed static righting reflex) and one female at 40 mg/kg bw/day. Since the incidence of these findings did not show an apparent relation to the dose and other animals of these dose group showed normal reflexes, this was considered not to be of toxicological relevance. Other functional observation parameters of this animal and those determined for other animals were normal.
ORGAN WEIGHTS
The following (statistically significant) changes in absolute organ weights and relative organ weights (organ to body weight ratio) were considered to be related to treatment:
− Higher liver weight in females at 40 and 160 mg/kg bw/day, and higher liver to body weight ratio in males at 160 mg/kg bw/day (mainly due one animal which also showed a higher liver weight) and females at 160 mg/kg bw/day.
− Lower thymus weight in males and females at 160 mg/kg bw/day (not statistically significant for females) and for males at 40 mg/kg bw/day, and lower thymus to body weight ratio in females at 160 mg/kg bw/day and males at 40 mg/kg bw/day,
− Higher adrenal weight and adrenal to body weight ratio in males and females at 160 mg/kg bw/day,
− Higher spleen weight and spleen to body weight ratio in males at 160 mg/kg bw/day (not statistically significant for absolute weights) and in females at 40 and 160 mg/kg bw/day,
− Lower prostate weight and prostate to body weight ratio in males at 160 mg/kg bw/day,
− Lower seminal vesicle weight and seminal vesicle to body weight ratio in males at 40 and 160 mg/kg bw/day (not statistically significant for seminal vesicle to body weight ratio in males at 40 mg/kg bw/day),
− Lower uterus weight in females at 160 mg/kg (not statistically significant).
The following statistically significant changes in organ weights were considered to be related to the lower terminal body weights and occurred without correlating morphological findings: lower brain weight in males at 160 mg/kg bw/day (and higher brain to body weight ratio in males at 40 and 160 mg/kg bw/day), lower heart weight in males at 40 and 160 mg/kg bw/day, lower thyroid weight in males at 160 mg/kg bw/day, lower kidney weights and higher kidney to body weight ratio in males at 160 mg/kg bw/day, lower epididymides weight in males at 160 mg/kg bw/day, and higher testes to body weight ratio in males at 160 mg/kg bw/day. The statistically significant higher kidney weight in females at 10 mg/kg bw/day occurred in the absence of a dose-related trend and remained within the range considered normal for rats of this age and strain. None of these changes were therefore considered to be of toxicological relevance.
GROSS PATHOLOGY
Treatment-related necropsy findings consisted of:
− Emaciation in 3/10 males and 6/10 females at 160 mg/kg bw/day.
− Mesenteric lymph nodes:
- Enlarged in 3/10 males and 4/10 females at 10 mg/kg, 9/10 males and 10/10 females at 40 mg/kg bw/day, and in 8/10 males and 9/10 females at 160 mg/kg bw/day,
- Irregular surface in 2/10 females at 160 mg/kg bw/day.
− Duodenum: Thickened in 3/10 males and 3/10 females at 40 mg/kg bw/day and 9/10 males and 8/10 females at 160 mg/kg bw/day.
− Jejunum: Thickened in 2/10 males and 4/10 females at 40 mg/kg bw/day and in 9/10 males and 8/10 females at 160 mg/kg bw/day.
− Ileum: Thickened in 1/10 males at 40 mg/kg bw/day and in 5/10 males and 3/10 females at 160 mg/kg bw/day.
− Skin:
- Subcutaneous thickening of the of hind and/or fore legs in 4/10 males at 40 mg/kg bw/day and in 3/10 males and 3/10 females at 160 mg/kg bw/day.
- Thickened/stiff joint in one male at 160 mg/kg bw/day.
− Spleen:
- Nodule/focus/foci in 2/10 males at 40 mg/kg bw/day and 2/10 males and 3/10 females at 160 mg/kg bw/day,
- Enlarged/thickened in 6/10 males and 2/10 females at 40 mg/kg bw/day and 4/10 males and 5/10 females at 160 mg/kg bw/day;
- Irregular appearance in 2/10 males at 40 mg/kg bw/dayand 2/10 males at 160 mg/kg bw/day;
- Grown together with peritoneum in 1/10 males at 40 mg/kg bw/dayand 3/10 males at 160 mg/kg bw/day.
− Liver:
- Grey/white foci in 1/10 females at 40 mg/kg bw/day and in 1/10 males and 4/10 females at 160 mg/kg bw/day;
- Enlarged in 1/10 males at 40 mg/kg bw/day and in 2/10 males and 2/10 females at 160 mg/kg bw/day;
- Pale discoloration in 1/10 males at 40 mg/kg bw/day and in 1/10 males and 2/10 females at 160 mg/kg bw/day;
- Accentuated lobular pattern in 1/10 males at 40 mg/kg bw/day and 1/10 females at 160 mg/kg bw/day.
− Thymus: Reduced in size in 1/10 males at 2.5 mg/kg bw/day, 1/10 males and 1/10 females at 40 mg/kg bw/day and in 3/10 males and 6/10 females at 160 mg/kg bw/day.
− Abdominal cavity:
- Nodule on epididymal adipose tissue in 1/10 males at 40 mg/kg bw/day,
- Epididymal adipose tissue grown together with spleen in 1/10 males at 40 mg/kg bw/day,
- Gelatinous epididymal adipose tissue in 1/10 males at 160 mg/kg bw/day.
− Adrenal glands:
- Enlarged in 3/10 males and 5/10 females at 160 mg/kg bw/day,
- Pale discoloration in 1/10 males at 40 mg/kg and in 3/10 males and 3/10 females at 160 mg/kg bw/day.
− Reproductive organs (prostate/seminal vesicle and uterus): Reduced in size in 4/10 (prostate) and 5/10 (seminal vesicles) males at 160 mg/kg bw/day and in 4/10 (uterus) females at 160 mg/kg bw/day.
The incidence of other necropsy findings among control and treated animals was within the background range of findings that are encountered among rats of this age and strain, and did not show a dose-related incidence trend. These necropsy findings were therefore considered to be of no toxicological relevance.
HISTOPATHOLOGY: NON-NEOPLASTIC
Treatment-related findings were observed in the mesenteric lymph node, duodenum, jejunum and ileum, joints, spleen, heart, liver, thymus, Peyer’s Patches, bone marrow, epididymides, prostate/seminal vesicles in males and uterus and adrenal glands in females. The findings in mesenteric lymph nodes and small intestines were considered primary targets. For the findings in joints it is unclear whether it is primary or secondary. All other organs are considered to be secondary targets, resulting from the findings in mesenteric lymph nodes and small intestines. The histopathology of the animals that were killed or that died before the end of the planned treatment period was more severe but similar in nature than the histopathology of the lower dosed rats.
Primary targets
Small intestines:
Duodenum:
- Foamy macrophages in the lamina propria of 9/10 males (3 minimal, 6 slight) and 7/10 females (6 minimal, 1 slight) at 40 mg/kg bw/day and 10/10 males (2 slight, 8 moderate) and 10/10 females (2 slight, 6 moderate, 2 marked) at 160 mg/kg bw/day.
- Granulocytic inflammation in 1/10 males (slight) at 40 mg/kg bw/day and in 7/10 males (3 minimal, 4 slight) and 4/10 females (1 minimal, 3 slight) of Group 5.
Jejunum:
- Foamy macrophages in the lamina propria of 4/10 males (minimal) and 3/10 females (minimal) at 10 mg/kg bw/day , in 10/10 males (2 minimal, 5 slight, 3 moderate) and 10/10 females (3 slight, 6 moderate, 1 marked) at 40 mg/kg bw/day and 10/10 males (4 moderate, 6 marked) and 10/10 females (3 moderate, 7 marked) at 160 mg/kg bw/day .
Ileum:
- Foamy macrophages in the lamina propria of 7/10 males (6 minimal, 1 slight) and 8/10 females (6 minimal, 2 slight) at 10 mg/kg bw/ day, in 10/10 males (3 minimal, 4 slight, 3 moderate) and 10/10 females (2 minimal, 8 slight) at 40 mg/kg bw/ day and 10/10 males (2 slight, 6 moderate, 2 marked) and 10/10 females (3 slight, 6 moderate, 1 marked) at 160 mg/kg bw/ day.
Mesenteric lymph nodes:
- Granuloma(s) with central necrosis in most cases in 7/10 (1 minimal, 4 slight, 1 moderate, 1 marked) males and 6/10 females (2 slight, 4 moderate) at 10 mg/kg bw/ day, in 10/10 males (1 slight, 3 moderate, 5 marked, 1 massive) and 9/10 females (2 minimal, 3 slight, 1 moderate, 2 marked, 1 massive) at 100 mg/kg bw/ day and in 9/10 males (1 slight, 3 moderate, 4 marked, 1 massive) and 7/10 females (1 minimal, 1 moderate, 3 marked, 2 massive) at 160 mg/kg bw/ day.
- Extranodal inflammation and/or necrosis (with/without peritonitis) in 5/10 males (2 minimal, 1 slight, 2 moderate) and 2/10 females (1 minimal, 1 moderate) at 10 mg/kg bw/ day, in 9/10 males (3 slight, 4 moderate, 2 marked) and 4/10 females (2 minimal, 2 moderate) at 40 mg/kg bw/ day and in 5/10 males (1 minimal, 3 slight, 1 moderate) and 6/10 females (1 minimal, 1 moderate, 4 marked) at 160 mg/kg bw/ day.
- Foamy macrophages in 2/10 males (minimal) 1/10 females (minimal) at 2.5 mg/kg bw/ day, in 9/10 males (1 minimal, 5 slight, 3 moderate) and 9/10 females (4 minimal, 2 slight, 3 moderate) at 10 mg/kg bw/ day, 8/10 males (4 slight, 3 moderate, 1 marked) and 8/10 females (3 slight, 3 moderate, 2 marked) at 40 mg/kg bw/ day and in 9/10 males (2 slight, 6 moderate, 1 marked) and 8/10 females (5 moderate, 3 marked) at 160 mg/kg bw/ day.
- (Increased) Macrophage foci in 6/10 males (2 minimal, 3 slight, 1 moderate) and 7/10 females (3 minimal, 4 slight) at 2.5 mg/kg bw/ day, 6/10 males (1 minimal, 2 slight, 2 moderate, 1 marked) and 4/10 females (2 minimal, 1 moderate, 1 marked) at 40 mg/kg bw/ day compared to 2/10 males and 2/10 females (all minimal) in the control group.
- Lymphoid hyperplasia in 1/10 males (slight) and 2/10 females (slight) at 10 mg/kg bw/ day, in 2/10 males (1 minimal, 1 slight) and 3/10 females (2 minimal, 1 slight) at 40 mg/kg bw/ day and in 4/10 females (1 minimal, 3 slight) at 160 mg/kg bw/ day.
- Sinus ectasia in 2/10 males (1 minimal, 1 slight) at 10 mg/kg bw/ day, 3/10 males (1 minimal, 1 moderate, 1 marked) and 2/10 (1 minimal, 1 slight) at 40 mg/kg bw/ day and 5/10 males (moderate) and 1/10 females (moderate) at 160 mg/kg bw/ day.
Unclear primary/secondary targets
Joints (hind and fore legs, in two males also sternum and vertebra):
- Arthritis in 4/10 males (3 moderate, 1 massive) at 40 mg/kg bw/ day and in 3/10 males (marked) and 3/10 females (2 marked, 1 massive) at 160 mg/kg bw/ day. At 160 mg/kg bw/ day, arthritis was also observed at the vertebral joints surrounding the thoracal spinal cord (2 slight) and at the intercostal joints of the sternum (1 minimal, 1 moderate).
- Exostosis in 2/10 males (1 marked, 1 massive) at 40 mg/kg bw/ day and in 3/10 males (2 moderate, 1 marked) and 1/10 females (moderate) at 160 mg/kg bw/ day. Exostosis was also noted in 2/10 males at 160 mg/kg bw/ day in the thoracal and/or cervical vertebrae.
- Reduced bone in joint of legs in 1/10 males (marked) at 40 mg/kg bw/ day and in 1/10 males (slight) at 160 mg/kg bw/ day and in sternum in 1/10 males of Group 4 (minimal) and 5/10 males of Group 5 (3 minimal, 1 slight, 1 moderate).
Secondary targets
Spleen:
- Necrotizing inflammation, intra- and/or extra-splenic in 2/10 males (1 moderate, 1 marked) and 1/10 females (slight) at 40 mg/kg bw/ day and in 2/10 males (1 moderate, 1 marked) and 2/10 females (marked) at 160 mg/kg bw/ day.
- Inflammation of mixed inflammatory cells in surrounding tissue in 1/10 males at 100 mg/kg bw/ day (slight) and in 3/10 males (moderate) at 160 mg/kg bw/ day
- Hemopoietic foci (increased above background severity of slight) in 1/10 males (marked) and 3/10 females (2 moderate, 1 marked) at 40 mg/kg bw/ day and in 2/10 males (1 marked, 1 massive) and 4/10 females (1 moderate, 1 marked, 2 massive) at 160 mg/kg bw/ day.
Liver:
- Granulomatous lesions with central necrosis in 2/10 females (moderate) at 10 mg/kg bw/ day, in 3/10 females (1 minimal, 1 moderate, 1 marked) at 40 mg/kg bw/ day and in 3/10 males (1 minimal, 1 moderate, 1 marked) and 4/10 females (2 moderate, 1 marked, 1 massive) at 160 mg/kg bw/ day.
- Sinusoidal leukocytosis in 1/10 females at 10 mg/kg bw/ day (minimal), in 3/10 males (2 slight, 1 moderate) and 1/10 females (slight) at 40 mg/kg bw/ day and in 4/10 males (1 minimal, 2 slight, 1 moderate) and 7/10 females (1 minimal, 3 slight, 3 moderate) at 160 mg/kg bw/ day.
- Foamy macrophage foci in 3/10 females (1 minimal, 1 slight, 1 moderate) at 40 mg/kg bw/ day and 1/10 females (slight) at 160 mg/kg bw/ day.
- Increased mitosis in 1/10 males (marked) at 40 mg/kg bw/ day and in 2/10 females (moderate) at 160 mg/kg bw/ day.
- Diffuse basophilia in 1/10 males (moderate) at 40 mg/kg bw/ day and in 3/10 females (2 moderate, 1 marked) at 160 mg/kg bw/ day.
Heart:
- (Epi/myo)carditis in 1/10 males (1 moderate) at 40 mg/kg bw/ day and in 2/10 males (moderate) and 1/10 females (slight) at 160 mg/kg bw/ day.
Thymus:
- Lymphoid atrophy in 3/10 males (1 minimal, 1 slight, 1 moderate) at 40 mg/kg bw/ day and in 3/10 males (1 minimal, 1 marked, 1 massive) and 8/10 females (2 minimal, 1 slight, 2 marked, 3 massive) at 160 mg/kg bw/ day.
Bone marrow (sternum):
- Myeloid hyperplasia in 4/10 males (3 minimal, 1 slight) and 3/10 females (minimal) at 10 mg/kg bw/ day, in 9/10 males (4 slight, 4 moderate, 1 marked) and 5/10 females (3 minimal, 1 slight, 1 moderate) at 40 mg/kg bw/ day and in 10/10 males (1 minimal, 5 slight, 1 moderate, 3 marked) and 9/10 females (1 slight, 6 moderate, 2 marked) at 160 mg/kg bw/ day.
- Megakaryocytosis present (no severity given) in 1/10 males and 3/10 females at 160 mg/kg bw/ day
Peyer’s Patches:
- Lymphoid atrophy in 3/10 males (minimal) at 40 mg/kg bw/ day and in 8/10 males (3 minimal, 5 slight) and 1/8 females (minimal) at 160 mg/kg bw/ day.
Adrenal glands:
- Diffuse cortical hypertrophy in 4/10 females (1 minimal, 2 slight, 1 moderate) at 160 mg/kg bw/ day.
Reproductive organs:
Epididymides:
- Inflammation of mixed inflammatory cells/granulomatous inflammation in surrounding tissue in 3/10 males (2 minimal, 1 slight) at 10 mg/kg bw/ day, in 7/10 males (3 minimal, 2 slight, 2 moderate) at 40 mg/kg bw/ day and 3/10 males (2 moderate, 1 marked) at 160 mg/kg bw/ day.
Prostate gland:
- Reduced content in 6/10 males (1 slight, 2 moderate, 3 marked) at 160 mg/kg bw/ day.
- Acinar atrophy in 3/10 males (moderate) at 160 mg/kg bw/ day.
Seminal vesicles:
- Reduced content in 8/10 males (3 minimal, 1 slight, 4 moderate) at 160 mg/kg bw/ day.
- Glandular atrophy in 4/10 males (slight) at 160 mg/kg bw/ day.
Coagulation glands:
- Reduced content in 6/10 males (2 minimal, 4 moderate) at 160 mg/kg bw/ day.
Uterus:
- Inactive in 1/10 females at 40 mg/kg bw/ day and 7/10 females at 160 mg/kg bw/ day.
Uterine cervix:
- Inactive in 5/10 females at 160 mg/kg bw/ day.
Vagina:
- Epithelial atrophy in 9/10 females at 160 mg/kg bw/ day.
OTHER FINDINGS
No treatment-related changes in the estrous cycle length were apparent up to 40 mg/kg bw/day. At 160 mg/kg bw/day, estrous cycle length could not be determined, since the surviving females were sacrificed before more than one cycle length was completed. Estrous cycle length showed a regular pattern for all animals of all dose groups, except for one female at 40 mg/kg and one control female (resp. irregular and acyclic). The incidence of these abnormal cycle lengths was low and showed no dose-related trend, and was therefore considered to be of no toxicological relevance. - Dose descriptor:
- NOAEL
- Effect level:
- 2.5 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Adverse effects obserevd above 2,5 mg/kg bw/ day, primarily caused by excessive aggregation of foamy macrophages in the small intestines and its draining mesenteric lymph node.
- Critical effects observed:
- not specified
- Conclusions:
- A repeated dose 90-day oral toxicity study with exposure to C16-18, C18-unsaturated-alkyl dipropylene triamine by daily gavage in the rat was performed according to OECD guideline and GLP principles. Based on the data from this study a No Observed Adverse Effect Level (NOAEL) of 2.5 mg/kg was established.
- Executive summary:
A repeated dose 90-day oral toxicity study with C16-18, C18-unsaturated-alkyl dipropylene triamine was performed according to OECD guidelines and GLP principles. Male and female rats (10/sex/exposure) were exposed to 0, 2.5, 10, 40 or 160 mg/ kg bw/ day by daily gavage. Based on the high mortality rate and signs of deteriorated health condition of animals at 160 mg/kg bw/ day, this high dose group was terminated after 11 weeks of dosing.
At 40 mg/kg bw/day, 3/10 males were killed in extremis in the last week of treatment. Rats treated with 40 and 160 mg/kg bw/day showed clinical signs including a hunched posture, piloerection, pallor, and swelling of the abdomen and/or legs, and an abnormal posture or gait, as well as reduced motor activity at 160 mg/kg bw/day. A lower body weight gain and food intake was recorded for males at 40 and 160 mg/kg (body weights were approximately 11 and 23% lower than controls at the end of treatment, respectively). At 10 mg/kg bw/day one male was found dead in Week 12. This animal displayed no clinical signs prior to death and had normal body weight gain, however it is not clear if this death was substance-related. Below 40 mg/kg bw/day, no clinical signs or changes in functional behaviour were noted.
Based on histopathological findings, the general deterioration in health condition and mortality at 40 and 160 mg/kg bw/day was considered to be due to an excessive aggregation of foamy macrophages in the small intestines and its draining mesenteric lymph node, containing poorly digestable test-article related material. The degradation of those cells was considered to have caused leakage and severe (necrotizing) inflammation both inside and outside the mesenteric lymph nodes, and included peritonitis and inflammation of the serosal tissues of for example spleen and epididymides. Hematogenic and/or lymphatic dissemination of cells/material originating from these lesions also resulted in the involvement of other organs such as liver, lung, heart and spleen causing different grades of inflammatory changes and necrosis. These changes supported necropsy lesions including enlarged mesenteric lymph nodes with irregular surface, thickening of the duodenum, jejunum and ileum, nodule/foci on the spleen, with enlargement/thickening/irregular surface of the spleen, spleen grown together with peritoneum, grey/white foci on the liver, enlargement, pale discoloration, and accentuated lobular pattern of the liver, a nodule in the epididymal adipose tissue, and epididymal adipose tissue grown together with spleen and gelatinous epididymal adipose tissue. These inflammatory processes were considered to have resulted in higher neutrophil counts at 40 and 160 mg/kg bw/day (resulting in higher total white blood cell counts). Other changes in blood at 40 and/or 160 mg/kg bw/day in males and/or females included a prolonged prothrombin time and higher platelet counts, higher alanine and aspartate aminotransferase activity, higher alkaline phosphatase activity, potassium and inorganic phosphate level, and lower total protein, albumin, total bilirubin, urea, creatinine, glucose, cholesterol, chloride and calcium level.
At 10 mg/kg bw/ day, changes in blood were confined to a higher inorganic phosphate level, and marginally higher neutrophil counts. At this dose, adverse histopathological findings were observed in the jejunum/ileum (minimally to slight foamy macrophages in lamina propria), mesenteric lymph nodes (general minimal to moderate foamy macrophages, accompanied by cases of granulomas with central necrosis, lymphoid hyperplasia, sinus ectasia), liver (granulomatous lesion with central necrosis in 2 males) and bone marrow (minimal myeloid hyperplasia in 7/40 animals).
At 2.5 mg/kg bw/day, histopathology findings were confined to foamy macrophages in the mesenteric lymph node in very few (3/40) animals at minimal degree and an increased incidence and severity compared to control in macrophage foci up to moderate degree, which is also observed at 10 mg/kg bw/day, but not at all at higher dose levels . Based relatively low severity, these mesenteric lymph node findings are considered not to be adverse. No treatment-related changes occurred in any of the other examined parameters at 2.5 mg/kg bw/day. Based on these results, a No Observed Adverse Effect Level (NOAEL) for C16-18, C18- unsaturated-alkyl dipropylene triamine of 2.5 mg/kg was established.
Reference
Chemical analyses showed that homogeneity of formulations was considered acceptable for the purpose of this study, and that formulations were prepared accurately, and were stable over at least 5 hours at room temperature or over at least 8 days under nitrogen at room temperature. The long term storage samples were stable at ≤-70°C for at least 38 days.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 2.5 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- 90-day study (OECD 408) sufficient to cover Annex IX requirements. Study is GLP compliant with Klimisch score 1. Results represent a conservative approach as it is based on read-across to a more toxic substance in the category.
- System:
- gastrointestinal tract
- Organ:
- ileum
- jejunum
- mesenteric lymph node
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- C16-18, C18-unsaturated-alkyl tripropylenetetraamine (Tallow tripropylenetetraamine) is a paste with mp of 31°C and has a vapour pressure of less than 4.7 x 10-5 Pa at 20°C (Based on read-across on coco-triamine, a similar product with shorter chain lengths). Its use is limited to industrial and professional users and does not involve the forming of aerosols, particles or droplets of an inhalable size. So exposure to humans via the inhalation route will be unlikely to occur.
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- C16-18, C18-unsaturated-alkyl tripropylenetetraamine (Tallow tripropylenetetraamine) is a paste with mp of 31°C and has a vapour pressure of less than 4.7 x 10-5 Pa at 20°C (Based on read-across on coco-triamine, a similar product with shorter chain lengths). Its use is limited to industrial and professional users and does not involve the forming of aerosols, particles or droplets of an inhalable size. So exposure to humans via the inhalation route will be unlikely to occur. In view of corrosive properties, exposures via inhalation when occurs would be characterised by local irritation.
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- C16-18, C18-unsaturated-alkyl tripropylenetetraamine (Tallow tripropylenetetraamine) is corrosive to the skin and is not expected to easily pass the skin. The skin is therefore not a preferred route when studying repeated dose systemic toxicity.
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- C16-18, C18-unsaturated-alkyl tripropylenetetraamine (Tallow tripropylenetetraamine) is corrosive to the skin.
Mode of Action Analysis / Human Relevance Framework
The most significant treatment-related changes in all studies performed on polyamines are effects on the small intestine and mesenteric lymph nodes. A relatively strong inflammatory reaction is also observed at high dose levels. These effects in the gastro-intestinal tract have consistently been observed with these polyamines, and are considered local effects related to the corrosive nature of the substances.
A mode of action has not been established but it is possible to suspect the known corrosivity to be at least partially involved. It is indicative that the observed effects are local and they are by some interpreted as phospholipidosis, something commonly observed following treatment with cationic amphiphilic material, including marketed pharmaceuticals, and considered to be non-adverse. When taking into consideration the relatively strong corrosive effects of this substance, and for substances belonging to the same group of chemicals, and the route of administration, it cannot be excluded that the overall toxicity reflects a point-of-first-contact effect.Additional information
Oral:
A combined repeated dose/reproduction screening toxicity study according to OECD 422 has been performed with Tallow tripropylenetetraamine. A rangefinder and maximum tolerated dose concluded that the maximum tolerated dose for Tallow tripropylenetetraamine is 300 mg/kg/day. In the full study Tallow tripropylenetetraamine was administered by daily oral gavage to male and female Wistar Han rats at dose levels of 0, 30, 100 or 300 mg/kg/day. The males were exposed for 2 weeks prior to mating, during mating, and up to termination (for at least 28 days). The females were exposed for 42-54 days, i.e. 2 weeks prior to mating, during mating, during post-coitum, and at least 4 days of lactation.
All animals at 300 mg/kg were killed in extremis on Day 10 of treatment. Microscopic findings in the stomach (including ulcers and erosions, corresponding to irregular surface of the forestomach at necropsy) were considered to have contributed to the moribundity. At necropsy, all sacrificed animals showed yellowish contents of the gastro-intestinal tract, irregular surface of the forestomach, dilation of the small intestines or caecum and reduced size of the thymus. Histopathological changes other than stomach effects noted at 300 mg/kg/day included hypertrophy of the epithelium of the duodenum, jejunum, ileum and caecum with or without foamy macrophages in the villi, foamy macrophages in the mesenteric lymph nodes, and lymphoid atrophy of the thymus, corresponding to dilation of the small intestines or caecum and reduced size of the thymus at necropsy.
At 100 mg/kg, one male and one female were killed in extremis on Day 27 and 38 of treatment, respectively. For one of these animals findings in the stomach (including an ulcer) were considered to have contributed to the moribundity, whilst for the other animal no clear cause of moribundity was established histopathologically. Clinical signs at 100 mg/kg/day primarily consisted of piloerection among females. In addition, lower absolute body weights and body weight gain were recorded during the Repro period for males and females, and for females also during post-coitum and lactation. Also, absolute and relative food consumption of females was lower than controls during the premating phase, and remained lower during the post-coitum period, but not during lactation. Clinical biochemistry changes in males and/or females consisted of higher alanine and aspartate aminotransferase activity, lower total protein and albumin levels, and higher total bilirubin, urea, cholesterol and bile acid levels. Haematological changes were confined to a higher relative and/or absolute neutrophil count, and higher platelet counts. Necropsy revealed lower liver, spleen, prostate, heart and thymus weight in males and/or females, which may at least in part be explained by the lower terminal body weights. Histopathological changes among the surviving animals consisted of hypertrophy of the epithelium and/or foamy macrophages in the villi of the duodenum, jejunum, ileum and caecum, lymphoid atrophy of the thymus and macrophage foci in the mesenteric lymph node.
At 30 mg/kg/day, a lower body weight gain was recorded for males during the Repro period without changes in food intake. Haematology showed a higher relative neutrophil count in females, but absolute neutrophil counts remained similar to controls. Clinical biochemistry parameters remained unaffected. Histopathological changes consisted of foamy macrophages in the villi of the ileum and jejunum, hypertrophy of the epithelium of the caecum and macrophage foci in the mesenteric lymph node.
As from this combined repeated dose/reproduction toxicity study no NOAEL could be derived, a subsequent 90-day study was performed on Tallow dipropylenetriamine to which cross-reading is done in order to derive a more reliable NOAEL.
Cross-reading and category approach:
Within the category of the Polyamine there are further studies available that clearly demonstrate the same toxicological profile for the various substances over this category, and also give some rules of thump to be considered when cross-reading between group members.
(See the document for the category justification for the polyamines that is attached to this dossier).
A repeated dose 90-day oral toxicity study with C16-18, C18-unsaturated-alkyl dipropylene triamine (Tallow dipropylenetriamine) was performed according to OECD 408 guidelines and GLP principles.Male and female rats (10/sex/exposure) were exposed to 0, 2.5, 10, 40 or 160 mg/ kg bw/ day by daily gavage. Based on the high mortality rate and signs of deteriorated health condition of animals at 160 mg/kg bw/ day, this high dose group was terminated after 11 weeks of dosing. At 40 mg/kg bw/day, 3/10 males were killed in extremis in the last week of treatment. Rats treated with 40 and 160 mg/kg bw/day showed clinical signs including a hunched posture, piloerection, pallor, and swelling of the abdomen and/or legs, and an abnormal posture or gait, as well as reduced motor activity at 160 mg/kg bw/day. A lower body weight gain and food intake was recorded for males at 40 and 160 mg/kg (body weights were approximately 11 and 23% lower than controls at the end of treatment, respectively). At 10 mg/kg bw/day one male was found dead in Week 12. This animal displayed no clinical signs prior to death and had normal body weight gain, however it is not clear if this death was substance-related. Below 40 mg/kg bw/day, no clinical signs or changes in functional behaviour were noted.
The NOAEL was determined at 2.5 mg/kg bw/day, based on effects observed at 10 mg/kg bw/day. At this level changes in blood were confined to a higher inorganic phosphate level, and marginally higher neutrophil counts. Also at 10 mg/kg bw/day, adverse histopathological findings were observed in the jejunum/ileum (minimally to slight foamy macrophages in lamina propria), mesenteric lymph nodes (general minimal to moderate foamy macrophages, accompanied by incidental cases of granulomas with central necrosis, lymphoid hyperplasia, sinus ectasia), liver (granulomatous lesion with central necrosis in 2 males) and bone marrow (minimal myeloid hyperplasia in 7/40 animals).
Further supportive information comes from read-across to other repeated dose studies in rat on Polyamines:
Sub-group |
Alkyl chain |
Study |
Results (in mg/kg bw/d) |
Diamines
|
C12/14
|
28-day study (OECD 407) |
NOAEL: 0.4 mg, based on moderate accumulations of foam cells in the jejunum and ileum, foam cell infiltration in mesenteric lymph node. |
90-day
|
NOAEL: 0.4 mg, based on enteropathy with foam cell accumulation in the small intestine and mesenteric lymph node with accompanying inflammatory changes seen in the mid and high dose groups. Not reversible during 90-day recovery period. |
||
Oleyl
|
14-day range finder |
NOAEL: 2 mg, enteropathy with foam cell accumulation in the small intestine and mesenteric lymph node with accompanying inflammatory changes seen in the mid and high dose groups. |
|
28-day |
NOAEL: 1.25 mg, based on enteropathy with foam cell accumulation in the small intestine and mesenteric lymph node with accompanying inflammatory changes seen in the mid and high dose groups. Not reversible during 14 day recovery period. |
||
Triamines
|
Coco |
OECD 422 |
LOAEL: 10 mg, based on foamy macrophage infiltration in the ileum and jejunum and foamy macrophage foci found in the mesenteric lymph nodes observed at this dose level. |
Tallow |
90-day |
NOAEL 2.5 mg/kg bw/day based on foamy macrophage infiltration in the ileum and jejunum. |
|
Y-triamines
|
C12
|
90-day |
NOAEL = 7-8 mg (m-f, dietary level at 100 ppm), based on enlargement of mesenteric lymph nodes with foamy macrophages, decreased BW gain, increased ASAT and ALAT levels, and tubular nephropathy at higher dose level. |
Chronic/carc |
NOAEL = 4 mg (dietary level ca. 100 ppm) based on increased ASAT, increase of lymphohistiocytic inflammatory reactions in the kidney, skeletal muscle and heart, and foamy macrophages in the mesenteric lymph nodes and alveoli of the lungs at next dose level. |
||
Tetraamines
|
Tallow |
OECD 422 |
LOAEL = 30 mg, based on foamy macrophage infiltration in the ileum and jejunum and foamy macrophage foci found in the mesenteric lymph nodes observed at this dose level. |
Oleyl |
28-day (OECD 407) |
Ongoing |
The most significant treatment-related changes in all studies performed on polyamines are effects on the small intestine and mesenteric lymph nodes. A relatively strong inflammatory reaction is also observed at high dose levels. These effects in the gastro-intestinal tract have consistently been observed with these polyamines, and are considered local effects related to the corrosive nature of the substances.
A mode of action has not been established but it is possible to suspect the known corrosivity to be at least partially involved. It is indicative that the observed effects are local and they are by some interpreted as phospholipidosis, something commonly observed following treatment with cationic amphiphilic material, including marketed pharmaceuticals, and considered to be non-adverse. When taking into consideration the relatively strong corrosive effects of this substance, and for substances belonging to the same group of chemicals, and the route of administration, it cannot be excluded that the overall toxicity reflects a point-of-first-contact effect. In that respect, considering that macrophages in the mesenteric lymph nodes are a local, porte d’entrée related effect due to the route of application, and not a systemic effect per se, the level of 2.5 mg/kg bw/day could also be argued to represent a NOAEL for local effects, and that the NOAEL for systemic effects is higher.
Dermal:
For dermal exposure no good overall NOAEL can be established as effects are rather characterized by local corrosive effects that are related to duration, quantity and concentration, than by systemic toxicity due to dermal uptake. The mode of action of for polyamines follows from its structure, consisting of an apolar fatty acid chain and a polar end of a primary amine linked to a secondary amine. The structure can disrupt the cytoplasmic membrane, leading to lyses of the cell content and consequently the death of the cell. The polyamines are completely protonated under environmental conditions which causes them to strongly adsorb to organic matter. This all leads to a low dermal absorption as is shown by a dermal absorption study performed on a structurally related branched triamine (Dodecyl dipropylene triamine) for 24 hours, resulted in a dermal penetration of less than 0.01% whereas 0.92% of the applied dose did pass the stratum corneum but remained further fixed in the skin. For the linear polyamines a similar and even lower (in case of higher alkyl chain lengths) dermal penetration can be expected.
An indication of the threshold for irritation can be obtained from a sensitisation study on one of the higher corrosive substance within PPA group: 0.5% in distilled water was found to be non-irritant (0.5 mL, 6 hrs, occlusive) on rabbit skin.
Inhalation:
Physical-chemical properties of Tallow tripropylenetetraamine indicate a low likelihood for exposure via inhalation, with a melting point of 31 °C, a boiling point > 300 °C and low vapour pressure (4.7 x 10-5 Pa at 20°C for the coco dipropylene triamine, with the shortest average alkyl chain length representing the highest vapour pressure for the group of polyamines).Justification for classification or non-classification
For this endpoint 'repeated dose toxicity by oral route' results from a combined repeated dose/reproduction toxicity screening (OECD 422) study on Tallow tripropylenetetramine is available. This study indicates a LOAEL of 30 mg/kgbw/day based on foamy macrophage infiltration in the ileum and jejunum and foamy macrophage foci found in the mesenteric lymph nodes observed at this dose level.
Classification for STOT-RE Cat. 2 is required in case of significant toxic effects at levels ≤ 100 mg/kgbw/d in case of standard 90-day study. In case of 28-day studies this can be multiplied by 3.
STOT-RE Cat.1 is required in case of significant toxicity at levels at levels ≤ 10 mg/kgbw/d in 90-day studies or ≤ 30 mg/kgbw/d in case of 28-day studies.
The OECD 422 study on Tallow tripropylenetetraamine indicted severe toxicity at 300 mg/kg causing the termination of the whole dose group making it eligible for Cat.2 classification. At 30 mg/kg/day, no severe toxicity was observed, and consequently, the criteria for GHS STOT-RE Cat.1 classification are not met. At 100 mg/kg/day also 2 animals had to be killed in extremis, which in one animal was related with gastro-intestinal corrosion.
Cross-reading to the 90 -day study (OECD 408) on Tallow dipropylenetriamine indicated severe toxicity at 160 mg leading to termination of this group after 11 weeks. Also at 40 mg/kg bw/day substance related mortality occurred as well as clinical signs and a 11% lower BW in males. The effects observed at 10 mg/kg bw/day do not impress as severe. This also results to a classification STOT-RE Cat.2
In conclusion: Available data results to classification for STOT-RE: Cat.2 [Warning]; H373: May cause damage to organs through prolonged or repeated exposure (based on mortality). Affected organs: Gastro intestinal system.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.